Baillie Gifford & Co’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Baillie Gifford & Co’s Portfolio CBPO Stock Details CBPO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-882,105	Closed	-$70.6M	–	231
2018 Q3	$70.6M	Sell	882,105 -465,177	-35%	-$43.3M	0.08%	108
2018 Q2	$134M	Buy	1,347,282 +8,968	+0.7%	+$775K	0.14%	83
2018 Q1	$108M	Sell	1,338,314 -9,481	-0.7%	-$766K	0.13%	84
2017 Q4	$106M	Buy	1,347,795 +12,975	+1%	+$1.08M	0.13%	86
2017 Q3	$123M	Sell	1,334,820 -42,673	-3%	-$4.1M	0.16%	83
2017 Q2	$156M	Sell	1,377,493 -17,791	-1%	-$1.99M	0.21%	78
2017 Q1	$140M	Sell	1,395,284 -17,761	-1%	-$1.9M	0.2%	78
2016 Q4	$152M	Sell	1,413,045 -30,107	-2%	-$3.52M	0.25%	72
2016 Q3	$180M	Sell	1,443,152 -17,600	-1%	-$2.08M	0.28%	69
2016 Q2	$155M	Buy	+1,460,752	New	+$170M	0.28%	68

Other funds holding CBPO

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

HSBC Holdings London, United Kingdom $239B AUM 42.32% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co's CBPO Position: Q4 2018 in Review

Baillie Gifford & Co sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2018, closing a stake of 882,105 shares — an estimated $70.6M sold.

Baillie Gifford & Co first reported a position in CBPO in Q2 2016 and held it in 10 quarters. The position peaked at $180M in Q3 2016. 67 funds tracked by Wall St. Rank hold CBPO as of Q4 2018.

Baillie Gifford & Co reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2018 after selling out during the quarter.
Baillie Gifford & Co sold 882,105 China Biologic Products Holdings, Inc. shares in Q4 2018, an estimated $70.6M.
Baillie Gifford & Co first reported a position in China Biologic Products Holdings, Inc. in Q2 2016 and held it in 10 quarters.
Baillie Gifford & Co's China Biologic Products Holdings, Inc. position peaked at $180M in Q3 2016.
67 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2018.

Based on Baillie Gifford & Co's 13F filing for Q4 2018, filed 14 Feb 2019.